Protocol Ledger

NCT07472517 · Phase III · RECRUITING

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Interventional Phase III clinical trial protocol NCT07472517 sponsored by Boehringer Ingelheim in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-13 Enrollment: 670 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07472517
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)670 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07472517
Protocol FieldVerified Registry Value
NCT IdentifierNCT07472517
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment670 participants (ESTIMATED)
Registered Start Date2026-04-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07472517
Hospital Research SiteLocationSite Profile
University of Arkansas for Medical SciencesLittle Rock, AROpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
University of Nebraska Medical CenterOmaha, NEOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI